sibutramine has been researched along with fexofenadine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JL; Chen, X; Dai, K; Fan, P; Fu, Y; Jaen, J; Li, L; Liang, L; Lindstrom, M; Mihalic, JT; Motani, A; Tang, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for sibutramine and fexofenadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sibutramine and fexofenadine
| Article | Year |
|---|---|
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Topics: Animals; Body Weight; Brain; Carbazoles; Cyclohexanecarboxylic Acids; Diet, High-Fat; Dogs; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Rats; Receptors, Pituitary Hormone; Structure-Activity Relationship | 2012 |